anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
DNA damage and its improper repair are the major source of genomic alterations responsible for many human diseases, particularly cancer. To aid researchers in understanding the underlying mechanisms of genome instability, a number of genome-wide profiling approaches have been developed to monitor DNA damage and repair events. The rapid accumulation of published datasets underscores the critical necessity of a comprehensive database to curate sequencing data on DNA damage and repair intermediates. Here, we present DNA Damage Atlas (DDA, http://www.bioinformaticspa.com/DDA/), the first large-scale repository of DNA damage and repair information. Currently, DDA comprises 6,030 samples from 262 datasets by 59 technologies, covering 16 species, 10 types of damage and 135 treatments. Data collected in DDA was processed through a standardized workflow, including quality checks, hotspots identification and a series of feature characterization for the hotspots. Notably, DDA encompasses analyses of highly repetitive regions, ribosomal DNA and telomere. DDA offers a user-friendly interface that facilitates browsing, searching, genome browser visualization, hotspots comparison and data downloading, enabling convenient and thorough exploration for datasets of interest. In summary, DDA will stand as a valuable resource for research in genome instability and its association with diseases.
Linguistic factors influence the likelihood of occurrence of stuttering instances on a certain word within an utterance. However, studies on the relationship between stuttering instances and linguistic factors of Turkish-speaking individuals are scarce. This study aimed to determine the syllable- and word-based measures of stuttering speech samples of Turkish-speaking school-aged children who stutter. Stuttering-like disfluencies (SLDs) and lexical categories were identified after transcription of 61 children's spontaneous speech samples (age range = 6-16). Syllable-, word- and utterance-level measures were employed. Syllable-based and word-based stuttering frequency findings were significantly different (p < .001); SLDs were more likely to occur at the utterance-initial (p < .001) and word-initial (p < .001) positions; content words were more likely to be stuttered and, there was a relation between the occurrence of SLDs and utterance length (p = .001). Since there is great variability between word-based and syllable-based measures, and SLDs tend to occur at word onsets, using word-based measures in Turkish would provide a measure of stuttering frequency that is comparable to the literature. Moreover, findings support that phrases requiring greater demands on utterance planning increase the possibility of occurrence of stuttering instances.
It is performed on a thin exercise mat divided into 40 small squares of 250 cm x 100 cm. Individuals are basically required to step in the direction of the length without stepping on the lines forming the squares. Before the CAE training, there will be a 5 minutes warm-up and then a minute cool down period. A total of 18 stepping patterns are planned to be used (6 beginner, 6 intermediate, 6 advanced). Basically, a pattern will be repeated 3-5 times and then the mirror image pattern will be repeated the same number of times. However, if the participant has difficulty in practicing the pattern, it will be repeated until he/she learns it, and after practicing the pattern 3 times without any errors, the next pattern will be used.
Perpendicular insertion about 0.8-1.2cun at bilateral sanyinjiao(SP6) acupoint.Then,bilateral SP6 were connected with Electronic Acupuncture Treatment Instrument (KWD-808-I,Yingdi, China). The frequency of the pulse was 20 Hz with a pulse duration of 200 us.Intensity of stimulus was depending on patient's tolerance.
The present solution to the medical triage problem is computer automated telephone triage system that gives customized medical advice to patients of doctors who have registered with the service. There ate two main modes of operation: a nurse-assisted mode, and a fully-automated mode. In the nurse-assisted system, a person desiring medical information calls the triage system and is connected to a nurse. The nurse asks a few questions and determines the caller's doctor, main symptom, and whether a high-risk medical condition exists. If there exists a serious condition then the nurse give appropriate instructions according to a triage protocol, Otherwise, the nurse connects the caller to the VoiceTriage program. This program plays back an audio message recorded by the caller's doctor giving the caller specific medical instructions to treat the caller's symptom. The fully-automated mode replaces the nurse-caller interaction with a computer-caller one. A main object of the present invention is to provide a patient with medical advice of his own doctor, in doctor's own voice to minimize confusion, increase quality of service and increase patient satisfaction with a triage systems and medical answering services.
Several therapeutic agents have been evaluated for the treatment of COVID-19, but only one, the antiviral drug called remdesivir administered intravenously, has shown to be effective in shortening the duration of the disease by 26.7% in critically ill patients. This proposal has the primary objective (1) to determine the effect of N-acetylcysteine (NAC; reducing substance and complementary viral intercepting action) and combination of NAC + bromhexine (BMX; viral protease inhibitor), on the clinical duration of COVID-19 evaluated on the 7th. day of outpatient follow-up, observing the score of clinical signs and symptoms of the disease. The study has as secondary objectives: (2) to assess the change in viral load by RT-qPCR of SARS-CoV-2 between the 1st, 7th, and 14th. days of the experimental protocol; (3) determine the action of NAC and BMX + NAC on the immune response using the rapid ELISA test (IgM / IgG) to be performed on the 14th. monitoring day of the experimental protocol; and (4) Assess the effect of NAC and BMX + NAC on the change in the serum level of inflammation biomarkers and reducing substances (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF- α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, PCR and procalcitonin; glutathione peroxidase-GPx; superoxide dismutase-SOD and catalase-CAT) of patients collected on the 1st. and 14 o. study days. The study will be a prospective, double-blind, placebo control and randomized clinical trial of a total of 219 patients, 73 for each treatment group, with mild to moderate disease, equal to or above 18 years of age, with clinical signs and symptoms. of COVID-19 and certified by the RT-qPCR test for the detection of SARS-CoV-2 viral load. The study will be carried out using the Surveillance, Service and Research Network - REVAP-C19, NUBIMED, FAMED, UFC, Fortaleza, CE in order to facilitate the efficiency of patients' entry into the study. The random groups of treatments will be: (1) Placebo control (Vitamin C - 500 mg / day, for 10 days); (2) N-acetylcysteine (NAC; 1800 mg / day, for 10 days); and (3) NAC (1800 mg / day, for 10 days) + Bromhexine Hydrochloride (BMX; 32 mg / day, for 10 days). The study has the perspective of evaluating the effectiveness of NAC alone or combined with BMX in the duration of the clinical score of mild to moderate cases of COVID-19. The study will also assess secondary parameters such as the effect of drugs on changing viral load, immune response, and changing the inflammatory reaction and reducing substances in the plasma of the study patients. In this sense, the trial plans to minimize the evolution of the disease to severe cases, thus alleviating the collapse of the health system and minimizing the social, economic and health disorders of the pandemic by SARS-CoV-2.
Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA \< 1.5 m2), 40mg (BSA 1.5 to \< 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA \>1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
PURPOSE: To provide an applicator for film-like membrane which can stably be adhered to skin for a long time, when the film-like membrane is applied on skin via a second adhesive layer formed in between a first face of a liner and a first face of a base layer, by making the film-like membrane adhere to skin and simultaneously peeling off from the base layer. CONSTITUTION: This film-like membrane is formed with a respiratory and nonocculusive extremely thin film-like membrane material. When a liner 6 is opened, the film-like membrane 2 is adhered to a base layer 4. After the film-like membrane 2 is applied on skin via an adhesive layer 3, the film-like membrane 2 is required to be easily peeled off the base layer 4. An adhesive layer 5 is made of a pressure sensitive material such as cross-liking acrylate copolymer. To make the film-like membrane be easily peeled off the base layer 4, a prescribed small area 5a is left without an adhesive on the adhesive layer 5. This is a consideration required also for a case, for instance, the film-like membrane 2 is temporarily fixed by heat sealing, etc. When acrylate polymer is used as the adhesive, a material the same as one used on the adhesive layer 3 can be used for the adhesive layer 5.
The utility model relates to a joint plaster paste which comprises plaster blocks and extensible buffering bands. The plaster blocks comprise first plaster blocks and second plaster blocks. Each two adjacent first plaster blocks are connected through one buffering band. One second plaster block is arranged among four adjacent first plaster blocks. A mucilage glue layer is arranged on the plaster blocks. The joint plaster paste has the advantages that extension and contraction of the buffering bands can meet requirements of joint moving, air holes are beneficial for ventilation and breathability of skin, the joint skin environment is improved, the single treatment effect of traditional plaster is changed, and double curative effects of two medicines are achieved.
PROBLEM TO BE SOLVED: To obtain a massaging cosmetic for eye having improved massaging effect and blood flow accelerating effect and remarkably improving the dark ring and shade under the eye by including a water-soluble polymer, an oil and a blood flow improving agent. SOLUTION: The objective cosmetic contains (A) a water-soluble polymer, (B) an oil and (C) a blood flow improving agent. The component A is natural water-soluble polymer, semisynthetic water-soluble polymer, etc., as well as synthetic water-soluble polymer such as polyvinyl alcohol and its amount is preferably 0.01-2 wt.%. A conventional ingredient for cosmetic such as petrolatum, stearyl alcohol and dimethylpolysiloxane can be used as the component B and its amount is preferably 1-30 wt.%. Materials usable as the component C are conventional ingredients for cosmetic, e.g. an extract of a plant such as arnica and Panax ginseng in addition to vitamin E, its ester, nicotinamide, etc., and the amount of the component C is preferably 0.01-5 wt.%.
Diabetes mellitus (DM) is the most important metabolic disease that can affect almost every organ system in the body. Although diabetes causes many macrovascular and microvascular complications, one of the rare microvascular complications is peripheral neuropathy. One of the common complementary and integrative applications in the management of diabetic peripheral neuropathy is foot massage. The aim of this study is to evaluate the effect of self-foot massage on peripheral neuropathic pain, peripheral skin temperature and patient comfort in individuals with diabetes. Individuals participating in the study will be divided into intervention and control groups. The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. There will be no additional application other than routine to the control group, data collection forms will be applied and recorded at the beginning of the study and at the end of four weeks. In the collection of data, "Individual Description Form, Visuel Analog Scale- (VAS), DN4 Pain Questionnaire and General Comfort Questionnaire- Short form" will be used. In addition, peripheral skin temperature will be measured with a skin thermometer.
BACKGROUND: Postoperative pulmonary complications (PPCs) are associated with postoperative mortality and prolonged hospital stay. Although intraoperative mechanical ventilation (MV) is a risk factor for PPCs, strategies addressing weaning from MV are understudied. In this systematic review, we evaluated weaning strategies and their effects on postoperative pulmonary outcomes.
METHODS: Our protocol was registered on PROSPERO (CRD42022379145). Eligible studies included randomised controlled trials and observational studies of adults weaned from MV in the operating room. Primary outcomes included atelectasis and oxygenation; secondary outcomes included lung volume changes and PPCs. Risk of bias was assessed using the Cochrane Risk of Bias (RoB2) tool, and quality of evidence with the GRADE framework.
RESULTS: Screening identified 14 randomised controlled trials including 1719 patients; seven studies were limited to the weaning phase and seven included interventions not restricted to the weaning phase. Strategies combining pressure support ventilation (PSV) with positive end-expiratory pressure (PEEP) and low fraction of inspired oxygen (FiO2) improved atelectasis, oxygenation, and lung volumes. Low FiO2 improved atelectasis and oxygenation but might not improve lung volumes. A fixed-PEEP strategy led to no improvement in oxygenation or atelectasis; however, individualised PEEP with low FiO2 improved oxygenation and might be associated with reduced PPCs. Half of included studies are of moderate or high risk of bias; the overall quality of evidence is low.
CONCLUSIONS: There is limited research evaluating weaning from intraoperative MV. Based on low-quality evidence, PSV, individualised PEEP, and low FiO2 may be associated with reduced postoperative pulmonary outcomes.
SYSTEMATIC REVIEW PROTOCOL: PROSPERO (CRD42022379145).
Do not use Proctocort ®Suppositories unless adequate proctologic examination is made. 

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection, the use of an appropriate antifungal or anti-bacterial agent should be instituted. If a favorable response does not occur promptly, Proctocort ®Suppositories should be discontinued until the infection has been adequately controlled. 

Carcinogenesis: No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories. 

Pregnancy Category C: In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women. Proctocort ®Suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. 

Nursing Mothers:It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Proctocort ®Suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
FIELD: medicine. ^ SUBSTANCE: the invention relates to medicine and pharmaceutics, in particular, to creation of pharmaceutical composition in the form of suspension with anti-shock and anti-allergic action. The pharmaceutical composition with said actions contains dexamethasone sodium phosphate and Ç£Micellate of calcium carbonate and magnesiumÇ. The pharmaceutical compositions also contain sodium hyalurate, alcohol, Nipagin, fructose and water. A variant of the invention is a suspension which additionally contains sodium fluoride and ascorbic acid. Research was carried out and it proved that the offered pharmaceutical compositions have expressed specific pharmacological effect, they express anti-shock action, and have no toxic effect with various doses and various routes for experimental animals. The compositions have no irritant effect, sensibilizing action was not expressed. ^ EFFECT: the offered pharmaceutical compositions are effective and safe medication and can be used to treat state of shock, suitable for treatment of patients additionally suffering from diabetes mellitus. ^ 2 cl, 2 ex, 1 tbl, 3 dwg
FIELD: medicine.SUBSTANCE: method includes three main steps. The first is the compensatory stage, which uses known methods of combined drug treatment, aimed at a transfer to a subacute or compensated stage of the disease. At the recovery stage, chondroptic peptide bioregulators VitOrgan are introduced according to a certain scheme. The bioregulators are injected slowly by jets based on 0.5% novocaine solution or saline solution mixed with 10 ml of 30% sodium thiosulfate solution up to 20 ml. Or dropwise introduction is performed, while the drug is dissolved in 100 or 200 ml of saline solution, or 200 ml of Reamberin, introduction rate is 50-60 drops per minute. Intravenous drugs administration is combined with subcutaneous or intramuscular administration of peptide bioregulators, including in combination with vascular and vasoactive agents. The rehabilitation phase involves the use of techniques such as massage, manual and osteopathic treatment techniques, physical therapy, therapeutic exercises, as well as methodologies aimed at body purification. Peptide bioregulators, vasoactive drugs and chondroprotectors are also used.EFFECT: method allows to significantly accelerate the process of patient recovery and achieve a lasting result.23 cl, 2 ex, 4 dwg
The invention provides pharmaceutical compositions, methods for the treatment of and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. RYGB, as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including T2D and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome. In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.
BACKGROUND: Chronic Lymphocytic Leukemia (CLL) is characterized by the expansion of CD19+ CD5+ B cells but its origin remains debated. Mutated CLL may originate from post-germinal center B cells and unmutated CLL from CD5+ mature B cell precursors. Irrespective of precursor types, events initiating CLL remain unknown. The cytokines BAFF and APRIL each play a significant role in CLL cell survival and accumulation, but their involvement in disease initiation remains unclear.
METHODS: We generated novel CLL models lacking BAFF or APRIL. In vivo experiments were conducted to explore the impact of BAFF or APRIL loss on leukemia initiation, progression, and dissemination. Additionally, RNA-seq and quantitative real-time PCR were performed to unveil the transcriptomic signature influenced by BAFF in CLL. The direct role of BAFF in controlling the expression of tumor-promoting genes was further assessed in patient-derived primary CLL cells ex-vivo.
RESULTS: Our findings demonstrate a crucial role for BAFF, but not APRIL, in the initiation and dissemination of CLL cells. In the absence of BAFF or its receptor BAFF-R, the TCL1 transgene only increases CLL cell numbers in the peritoneal cavity, without dissemination into the periphery. While BAFF binding to BAFF-R is dispensable for peritoneal CLL cell survival, it is necessary to activate a tumor-promoting gene program, potentially linked to CLL initiation and progression. This direct role of BAFF in controlling the expression of tumor-promoting genes was confirmed in patient-derived primary CLL cells ex-vivo.
CONCLUSIONS: Our study, involving both mouse and human CLL cells, suggests that BAFF might initiate CLL through mechanisms independent of cell survival. Combining current CLL therapies with BAFF inhibition could offer a dual benefit by reducing peripheral tumor burden and suppressing transformed CLL cell output.
The experimental condition involves participants listening to a 16-minute recording of a body scan meditation. The body scan condition guides participants to focus on their bodily sensations separately, then together as a whole.
This study aimed to assess the frequency and association between transthyretin-derived (ATTR) amyloidosis and sarcoidosis in a large autopsy cohort including many cases of sudden cardiac death (SCD). We identified 73 sporadic ATTR amyloidosis cases and 11 sarcoidosis cases, among which we found two cases with concomitant ATTR amyloidosis and sarcoidosis (2.4% of all cases; 2.7% within the sporadic ATTR group). The first case involved a 92-year-old man who experienced SCD. In this patient's heart, we observed ATTR deposition and noncaseating epithelioid granulomas consistent with sarcoidosis. Focally, ATTR deposits and granulomas co-localized, with histiocyte phagocytosis of transthyretin-immunoreactive fragments. However, in most lesions, they were distributed independently. The second case was that of an 86-year-old woman who also experienced SCD. In this patient, we detected ATTR deposition in the heart and lung, while noncaseating epithelioid granulomas were only observed in the lung, liver, kidney, and thyroid. Furthermore, no co-localization of the two lesions was observed. Based on these findings, we concluded that the coexistence of ATTR amyloidosis and sarcoidosis was likely coincidental. Nevertheless, despite the rarity of the combination of these two diseases, it should be recognized as a potential cause of SCD, especially among elderly people.